Real-world results of immune checkpoint inhibitors from the Taiwan National Health Insurance Registration System
Hsieh ST, Ho HF, Tai HY, Chien LC, Chang HR, Chang HP, Huang YW, Huang JJ, Lien HJ, Huang LY, Lee PC
Record ID 32018002656
English
Authors' objectives:
Immune checkpoint inhibitors (ICIs) are a major advance in cancer treatment, but their payment benefits are unclear, resulting in financial risk. In Taiwan, the National Health Insurance Administration (NHIA) has adapted risk-sharing mechanisms to cover ICIs by collecting and assessing real-world evidence, such as case registration data, to adjust benefit packages for each medication, increase payment benefits of ICIs, and enable national health insurance sustainability.
Authors' results and conclusions:
Under the national registration tracking system, Taiwan's high-cost drug policy has enabled access to new medicines and maximized patient benefits.
Authors' recommendations:
The NHID RWD indicate some differences in the effectiveness of ICIs for cancer patients in Taiwan versus Europe/the United States. To monitor trends in precision medicine for cancer, the NHIA collects and evaluates RWE, such as registered case data, which serves as a frame of reference for adjustment decisions on the benefits of such medications. New technologies should be used to identify suitable patients for medication to enhance ICIs payment benefits. Moreover, given the rapid increase in healthcare expenditures in many countries, the challenges associated with the high costs of medicines, and the uncertainty of their effectiveness, Taiwan has implemented a policy for high-cost medicines. It also uses MEAs to establish a national registry for immunotherapy. However, HTA should be used to support sustainable healthcare.
Authors' methods:
This nationwide, multicenter, retrospective cohort study assessed the real-world use, effectiveness, and safety of ICIs reimbursed by the NHIA for treating multiple advanced cancers in Taiwan. We obtained data mainly from the NHIA Immune Checkpoint Inhibitor Registry Database.
Details
Project Status:
Completed
Year Published:
2021
URL for published report:
https://www.europeanreview.org/article/27097
URL for additional information:
English (Abstract and published paper) Full HTA report in Chinese (Mandarin)
English language abstract:
An English language summary is available
Publication Type:
Full HTA
Pubmed ID:
34787857
MeSH Terms
- Neoplasms
- Immune Checkpoint Inhibitors
- Antibodies, Monoclonal, Humanized
- Nivolumab
- Antineoplastic Agents, Immunological
- Registries
Keywords
- Immune checkpoint inhibitors
- Real-world data
- National registration tracking system.
Contact
Organisation Name:
Center for Drug Evaluation
Contact Address:
3F.,No.465, Sec.6, Zhongxiao E. Rd., Taipei 11557, Taiwan. R.O.C.
Contact Name:
Li Ying (Grace) Huang
Contact Email:
lyhuang277@cde.org.tw
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.